Przyczynowość stanów mentalnych w modelach naukowych. Próba alternatywnego uzasadnienia antynaturalizmu eksplanacyjnego Urszuli Żegleń

An antinaturalist defense of causality of mental states. The argument is based on the properties of causal models in cognitive research. Bibliografia prac przywołanych w tekście Damasio A., 1994/1999, Błąd Kartezjusza. Emocje, rozum i ludzki mózg, tłum. M. Karpiński, Poznań: Rebis. Davidson D., 1963/2001, „Actions, reasons, and causes”, w: (Davidson 2001), s. 3-19. Davidson D., 1967/2001, „Causal relations”, w: (Davidson 2001), s. 149-62. Davidson D., 1970/2001, „Mental events”, w: (Davidson 2001), s. 207-25. Davidson D., 1976/2001, „Hempel on explaining action”, w: (Davidson 2001), s. 261-75. Davidson D., 2001, Essays on actions and events, Oxford: Clarendon. Farmer A., McGuffin P., Williams J., 2002, Measuring psychopathology, Oxford: Oxford University Press. Freedman D. A., Petitti D. B., 2002, „Salt, blood pressure, and public policy”, International Journal of Epidemiology, t. 31, s. 319–320. Greyson B., 2000, „Near-death experiences”, w: Varieties of anomalous experience. Examining the scientific evidence, red. E. Cardeña, S. J. Lynn i S. Krippner, Washington, DC: American Psychological Association, s. 315-52. Judycki S., 1995, Umysł i synteza, Lublin: RW KUL. Judycki S., 2000, „Transkauzalność a determinizm”, Kognitywistyka i media w edukacji, t. 3, s. 73-86. Kawalec P. 2005, „Understanding science of the new millennium”, http://philsci archive.pitt.edu/archive/00002558/ Kawalec P., 2006, Jak odkryć przyczynę? Studium z ogólnej metodologii i filozofii nauki, Lublin 2006, w przygotowaniu. Kim J., 1998/2002, Umysł w świecie fizycznym, tłum. R. Poczobut, Warszawa: IFiS PAN. Lauritzen S., 1996, Graphical models, Oxford: Clarendon. Menzies P., 2003, „The causal efficacy of mental states”, w: Physicalism and mental causation. The metaphysics of mind and action, red. S. Walter i H.-D. Heckmann, w druku. Pearl J., 2000, Causality. Models, reasoning, and inference, Cambridge: Cambridge University Press. Piłat R., 1999, Umysł jako model świata, Warszawa: IFiS PAN. Rosenbaum P., 2002, Observational studies, Nowy Jork: Springer. Sabom M., 1998, Life and death. One doctors’s fascinating account of near-death experiences, Grand Rapids: Zondervan. Spirtes P., Glymour C., Scheines R., 2000, Causation, prediction, and search, Cambridge, MA.: MIT. van Fraassen B., 1980, The scientific image, Oxford: Clarendon. van Fraassen B., 2002, The empirical stance, New Haven: Yale University Press. Woodward J., 2003, Making things happen: a theory of causal explanation, Nowy Jork: Oxford University Press. Żegleń U., 2003, Filozofia umysłu, Toruń: A. Marszałek

Epistemic Reliability of Neyman-Pearson Hypothesis Testing and Its Pragmatic Value-Laden Unequal Error Risk Setting

In this paper, we examine whether N-P can be seen as principally satisfying, in a minimal sense, some general epistemic standards and how pragmatic value-laden uneven setting of error probabilities can influence it. Using the concept of predictive value it is shown that Neyman-Pearson's theory of testing hypothesis offers at least minimal epistemic reliability only under the assumption that among the tested hypotheses the number of true hypotheses is equal to the number of false hypotheses. We also argue that N-P does not protect from the possible negative effects of the pragmatic value-laden unequal setting of error probabilities on N-P’s epistemic reliability. We show how pragmatic factors implemented in the form of the asymmetric setting of probabilities of two types of error may have a positive or negative impact on the epistemic reliability of N-P dependent on the case of the hypothesis tested and the assumption about the ratio of true to false hypotheses. More importantly, we argue that in the case of negative impact no methodological adjustment is available to neutralize it so in such cases the discussed pragmatic-value-ladenness of N-P inevitably compromises the goal of attainment of the truth

Neyman-Pearson Hypothesis Testing, Epistemic Reliability and Pragmatic Value-Laden Asymmetric Error Risks

We show that if among the tested hypotheses the number of true hypotheses is not equal to the number of false hypotheses, then Neyman-Pearson theory of testing hypotheses does not warrant minimal epistemic reliability (the feature of driving to true conclusions more often than to false ones). We also argue that N-P does not protect from the possible negative effects of the pragmatic value-laden unequal setting of error probabilities on N-P’s epistemic reliability. Most importantly, we argue that in the case of a negative impact no methodological adjustment is available to neutralize it, so in such cases the discussed pragmatic-value-ladenness of N-P inevitably compromises the goal of attaining truth

Pharmaceutical regulation in 15 European countries: review

In the context of pharmaceutical care, policy-makers repeatedly face the challenge of balancing patient access to effective medicines with affordability and rising costs. With the aim of guiding the health policy discourse towards questions that are important to actual and potential patients, this study investigates a broad range of regulatory measures, spanning marketing authorization to generic substitution and resulting price levels in a sample of 16 European health systems (Austria, Belgium, Denmark, England, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Poland, Portugal, Scotland, Spain and Sweden). All countries employ a mix of regulatory mechanisms to contain pharmaceutical expenditure and ensure quality and efficiency in pharmaceutical care, albeit with varying configurations and rigour. This variation also influences the extent of publicly financed pharmaceutical costs. Overall, observed differences in pharmaceutical expenditure should be interpreted in conjunction with the differing volume and composition of consumption and price levels, as well as dispensation practices and their impact on measurement of pharmaceutical costs. No definitive evidence has yet been produced on the effects of different cost-containment measures on patient outcomes. Depending on the foremost policy concerns in each country, different levers will have to be used to enable the delivery of appropriate care at affordable prices

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries

Objectives: The aim of this study was to characterize the reimbursement policy for orphan drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability and impact of clinical evidence, health technology assessment (HTA) procedure, selected economic indicators, and the drug type according to indications.Materials and methods: A list of authorized medicines with orphan designation and information about active substance, Anatomical Therapeutic Chemical (ATC) classification, and therapeutic area was extracted from the web-based register of the European Medicines Agency (EMA). A country-based questionnaire survey was performed between September 2021 and January 2022 in a group of selected experts from nine CEE countries (an invitation was sent to 11 countries). A descriptive and statistical analysis was conducted to determine statistical significance, correlations, between the drug or country characteristic and the positive recommendation or reimbursement of ODs.Results: The proportion of reimbursed orphan drugs differed between countries, ranging from 17.7% in Estonia to 49.6% in Hungary (p < 0.001). The odds that ODs were reimbursed were reduced in countries with a “strong” level of impact of drug safety and efficacy on reimbursement decisions (p=0.018), the presence of other additional specific clinical aspects (e.g., genomic data) considered in the reimbursement decision (p < 0.001) and mandatory (without exception) safety assessments (p=0.004). The probability that ODs were reimbursed was increased in countries with a “moderate” level of impact of drug safety and efficacy on reimbursement decisions (p=0.018), when reimbursement decisions are dependent on the EMA registration status and orphan drug designation (p < 0.001), the presence of the “positive HTA recommendation guarantees reimbursement” policy (p < 0.001), higher GDP per inhabitant (p=0.003), and higher healthcare expenditure (p < 0.001).Conclusion: We found that there are differences among CEE countries in the reimbursement of orphan drugs, and we identified aspects that may influence these differences. Safety, efficacy, and specific clinical aspect issues significantly influenced reimbursement decisions. Antineoplastic and immunomodulating agents drugs were the largest group of ODs and increased the chance of getting a positive recommendation. The higher GDP per inhabitant and healthcare expenditures per inhabitant were positively linked to the chance that an OD receives reimbursement

The European challenges of funding orphan medicinal products

Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU).To identify the different methods for public funding of OMPs in order to map the availability for rare disease patients, as well as to compare the public expenditures on OMPs in 8 EU member states.Information on the reimbursement status of 83 OMPs was collected in 8 countries by distinguishing standard and special reimbursements. In two consecutive years, the total public expenditures on OMPs were calculated by using annual EUR exchange rates. Annual total public expenditures were calculated per capita, and as a proportion of GDP, total public pharmaceutical and healthcare budgets. Differences between countries were compared by calculating the deviations from the average spending of countries.In 2015 29.4-92.8% of the 83 OMPs were available with any kind of public reimbursement in participant countries including special reimbursement on an individual basis. In Austria, Belgium and France more OMPs were accessible for patients with public reimbursement than in Bulgaria, Czech Republic, Hungary and Poland. Standard reimbursement through retail pharmacies and/or hospitals was applied from 0 to 41% of OMPs. The average annual total public expenditure ranged between 1.4-23.5 €/capita in 2013 and 2014. Higher income countries spent more OMPs in absolute terms. Participant countries spent 0.018-0.066% of their GDPs on funding OMPs. Average expenditures on OMPs were ranged between 2.25-6.51% of the public pharmaceutical budget, and 0.44-0.96% of public healthcare expenditures.Standard and special reimbursement techniques play different roles in participant countries. The number of accessible OMPs indicated an equity gap between Eastern and Western Europe. The spending on OMPs as a proportion of GDP, public pharmaceutical and healthcare expenditure was not higher in lower income countries, which indicates substantial differences in patient access to OMPs in favour of higher-income countries. Equity in access for patients with rare diseases is an important policy objective in each member state of the EU; however, equity in access should be harmonized at the European level

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries

Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant

Cartwright's Theorem and Procedural Approach to Causality

N. Cartwright's recent results on invariance under intervention and causality (2003) are reconsidered. Procedural approach to causality elicited in this paper and contrasted with Cartwright's apparently philosophical one unravels certain ramifications of her results. The procedural approach seems to license only a constrained notion of intervention and in consequence the "correctness to invariance" part of Cartwright's first theorem fails for a class of cases. The converse "invariance to correctness" part of the theorem relies heavily on modeling assumptions which prove to be difficult to validate in practice and are often buttressed by independently acquired evidence